BI Asset Management Fondsmaeglerselskab A S Decreases Position in Humana Inc. $HUM

BI Asset Management Fondsmaeglerselskab A S lessened its holdings in shares of Humana Inc. (NYSE:HUM) by 63.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 6,251 shares of the insurance provider’s stock after selling 10,808 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Humana were worth $1,601,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Humana by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider’s stock worth $3,652,890,000 after acquiring an additional 106,030 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Humana by 28.9% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,496,775 shares of the insurance provider’s stock valued at $1,151,759,000 after buying an additional 1,008,514 shares during the last quarter. Pzena Investment Management LLC raised its stake in shares of Humana by 1.0% during the 4th quarter. Pzena Investment Management LLC now owns 4,072,208 shares of the insurance provider’s stock valued at $1,043,015,000 after buying an additional 41,125 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Humana by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 3,184,569 shares of the insurance provider’s stock valued at $812,540,000 after buying an additional 23,732 shares during the last quarter. Finally, Capital International Investors purchased a new position in shares of Humana during the 3rd quarter valued at about $707,670,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Price Performance

NYSE:HUM opened at $364.11 on Wednesday. Humana Inc. has a 52 week low of $163.11 and a 52 week high of $365.22. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $43.72 billion, a PE ratio of 38.94, a price-to-earnings-growth ratio of 2.04 and a beta of 0.76. The stock’s 50-day moving average price is $255.95 and its 200-day moving average price is $234.19.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The firm had revenue of $39.65 billion for the quarter, compared to analysts’ expectations of $39.37 billion. During the same period last year, the firm earned $11.58 EPS. The company’s quarterly revenue was up 23.5% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, equities analysts expect that Humana Inc. will post 9 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.0%. The ex-dividend date is Friday, June 26th. Humana’s payout ratio is presently 37.86%.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Robert W. Baird reduced their price objective on Humana from $264.00 to $205.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Truist Financial lifted their price objective on Humana from $270.00 to $320.00 and gave the company a “hold” rating in a research note on Monday, June 1st. Sanford C. Bernstein reiterated an “outperform” rating and set a $425.00 price objective on shares of Humana in a research note on Wednesday, June 3rd. The Goldman Sachs Group lifted their price objective on Humana from $158.00 to $195.00 and gave the company a “sell” rating in a research note on Thursday, April 30th. Finally, Oppenheimer upgraded Humana from an “outperform” rating to an “outperform” rating in a research report on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, fourteen have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $286.13.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.